Literature DB >> 11768507

An in vitro system for the study of ultrasound contrast agents using a commercial imaging system.

V Sboros1, C M Moran, T Anderson, L Gatzoulis, A Criton, M Averkiou, S D Pye, W N McDicken.   

Abstract

An in vitro system for the investigation of the behaviour of contrast microbubbles in an ultrasound field, that provides a full diagnostic range of settings, is yet to be presented in the literature. The evaluation of a good compromise of such a system is presented in this paper. It is based on (a) an HD13000 ATL scanner (Bothell, WA, USA) externally controlled by a PC and (b) on the use of well-defined reference materials. The suspensions of the reference ultrasonic scattering material are placed in an anechoic tank. The pulse length ranges from 2 to 10 cycles, the acoustic pressure from 0.08 to 1.8 MPa, the transmit frequency from 1 to 4.3 MHz, and the receive frequency from 1 to 8 MHz. The collection of 256 samples of RF data, at an offset distance from the transducer face, was performed at 20 MHz digitization rate, which corresponds to approximately 1 cm depth in water. Two particle suspensions are also presented for use as reference scatterers for contrast studies: (a) a suspension of Orgasol (ELF Atochem, Paris, France) particles (approximately 5 microm mean diameter) and (b) a suspension of Eccosphere (New Metals & Chemicals Ltd, Essex, UK) particles (approximately 50 microm mean diameter). A preliminary experiment with the contrast agent Definity (DuPont Pharmaceutical Co, Waltham, MA) showed that the above two materials are suitable for use as a reference for contrast backscatter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768507     DOI: 10.1088/0031-9155/46/12/316

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  1 in total

1.  The bubble cloud as an N-degree of freedom harmonic oscillator.

Authors:  V Leroy; M Devaud; T Hocquet; J-C Bacri
Journal:  Eur Phys J E Soft Matter       Date:  2005-05-06       Impact factor: 1.890

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.